The Feist-Weiller Cancer Center (FWCC) Minority-Based Community Clinical Oncology Program (MB-CCOP) aims to provide increased access to state-of-the-art cancer prevention care, and control through NCI-sponsored clinical trials to the minority and indigent populations in the northwestern section of La., and throughout the state of Louisiana. The Feist-Weiller Cancer Center was established at the Louisiana State University Health Science Center in Shreveport (LSUHSC-S) to provide multidisciplinary cancer care, and clinical and translational research targeted to the unique population in Northwest La, which will improve the public health by decreasing cancer incidence and deaths. The population was plagued with high rates of poverty, low literacy and low levels of education, little access to modern approaches to prevention, detection, and treatment of cancer, and often presented with late stages of cancer, Fifty-five percent of newly diagnosed cancer patients at LSUHSC-S are African-Americans, With the destruction of Charity and University Hospitals in New Orleans by hurricane Katrina, LSUHSCS is now the only intact tertiary care hospital providing care to the state's indigent population and has become the major site for treatment of patients with leukemia and lymphoma, and those requiring bone marrow transplant. To provide local access to cancer clinical trials for the increased referral area, the FWCC will continue to strengthen and expand its organizational and operational base in order to support a structure to effectively implement a program to provide a multidisciplinary approach to cancer care and prevention for patients referred to the FWCC and in the patients'local communities. The FWCC MB-CCOP has provided access to NCI-sponsored clinical trials and research coordinator support at outlying sites. Education will be provided to community physicians through teleconferencing cancer tumor boards. Outreach programs to educate the indigent and minority population about cancer prevention, screening, and treatment, and clinical trials available through the FWCC MB-CCOP will be conducted with the assistance of the Louisiana Cancer Control Partnership, an organization dedicated to reducing cancer disparities by providing education, screening, referrals, information dissemination, and other resources in the minority and underserved communities. As well, the FWCC Partners in Wellness Free cancer screening program will be utilized to spread this valuable educational information. Since the FWCC has been founded, our approach to cancer has resulted in outcomes at LSUHSC-S at least as good as the national average and far better than Louisiana as a whole which ranks 49th in cancer mortality. The FWCC has a history of greater than 40% minority accrual to SWOG, CTSU, and NCI treatment and prevention studies, as well as industry, in-house, and translational research protocols. Plans to expand minority access and accrual are detailed in this application.
The provision of a multidisciplinary cancer care program to a population plagued by poverty, illiteracy, and little access to innovative approaches to the prevention, detection and treatment of cancer will serve to educate and treat this population, thereby decreasing cancer incidence and deaths.
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Advani, Anjali S; McDonough, Shannon; Copelan, Edward et al. (2014) SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233-7|
|Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5|
|Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42|
|Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900|
|Skinner, Eila C; Goldman, Bryan; Sakr, Wael A et al. (2013) SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. J Urol 190:1200-4|
|Mahadevan, Daruka; Unger, Joseph M; Spier, Catherine M et al. (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371-9|
|Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25|
|Petersdorf, Stephen H; Kopecky, Kenneth J; Slovak, Marilyn et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854-60|
|Sucheston, Lara E; Zhao, Hua; Yao, Song et al. (2011) Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130:993-1002|
Showing the most recent 10 out of 16 publications